FERMENTABSEFermenta Biotech LtdHighNeutral
Announced Tue, 26 May · 14:30 IST

Annual General Meeting, Financial Results and Dividend

Revenue DeclinePat NegativeEbitda Margin CompressionExceptional ItemResults View source PDF

FERMENTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.6%1-day move
₹307.00
prior close
₹300.85
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.9-2.3-2.6-2.8-3.6-3.8-2.0+3.2+2.6+10.4+4.0+15.6+43.2
Up moveDown movePending
AI summary

Fermenta Biotech Ltd reported FY2026 audited results showing revenue decline on both standalone and consolidated basis. Standalone total income fell to Rs. 44,220.95 Lakhs from Rs. 47,415.16 Lakhs (down ~6.7%), while consolidated income dropped more sharply to Rs. 48,129.58 Lakhs from Rs. 54,781.46 Lakhs (down ~12%). PAT on standalone basis declined from Rs. 6,761.54 Lakhs to Rs. 6,428.36 Lakhs (~5% decline), and on consolidated basis from Rs. 7,640.28 Lakhs to Rs. 7,025.43 Lakhs (~8% decline). The Board recommended a final equity dividend of Rs. 3.75 per share (75% payout) subject to shareholders' approval at the 74th AGM scheduled for August 11, 2026. Statutory auditors SRBC & Co. LLP issued unmodified opinions on both standalone and consolidated financial statements. Exceptional items included Rs. 907.14 Lakhs recovery from previously provided receivables and Rs. 219.56 Lakhs towards employee benefit obligations under new Labour Codes.

Likely market impact

The revenue and profit decline for FY2026 is concerning for shareholders. While the dividend payout ratio of 75% provides some return, the company's top-line contraction and PAT decline may put pressure on the stock price in the near term.